brivaracetam

GPTKB entity

Statements (64)
Predicate Object
gptkbp:instance_of gptkb:Antihero
gptkbp:approves gptkb:European_Union
gptkb:United_States
2016-02-29
gptkbp:atccode N03 AX22
gptkbp:availability prescription only
gptkbp:brand gptkb:Briviact
gptkbp:casnumber 357336-20-0
gptkbp:chemical_formula C12 H14 N2 O2
gptkbp:class anticonvulsants
gptkbp:clinical_trial Phase III
gptkbp:clinical_use seizure control
gptkbp:composed_by from 2-oxo-1-pyrrolidine acetic acid
gptkbp:contraindication hypersensitivity
gptkbp:developed_by gptkb:UCB_Pharma
gptkbp:drug_interactions CYP2 C19 inhibitors
CYP3 A4 inducers
gptkbp:duration long-term
gptkbp:excretion urine
gptkbp:formulation gptkb:Software_Solutions
tablets
https://www.w3.org/2000/01/rdf-schema#label brivaracetam
gptkbp:indication partial-onset seizures
gptkbp:is_monitored_by side effects
seizure frequency
gptkbp:knockouts high
gptkbp:lifespan 8 to 9 hours
gptkbp:market_position available
gptkbp:mechanism_of_action SV2 A ligand
gptkbp:metabolism liver
gptkbp:patient_education recognizing side effects
importance of adherence
drug interactions awareness
gptkbp:patient_population adults and children
gptkbp:pharmacokinetics linear
modulates neurotransmitter release
gptkbp:price varies by region
gptkbp:provides_guidance_on dose adjustment for renal impairment
follow-up required
recommended for refractory epilepsy
gptkbp:regulatory_compliance FDA approved
EMA approved
gptkbp:research_focus new formulations
pediatric use
long-term safety
drug combinations
gptkbp:route_of_administration oral
gptkbp:side_effect gptkb:depression
anxiety
dizziness
fatigue
nausea
irritability
ataxia
insomnia
weight gain
somnolence
gptkbp:structure pyrrolidine derivative
gptkbp:treatment adjunctive therapy
gptkbp:type_of_care important for efficacy
gptkbp:used_for gptkb:epilepsy
gptkbp:bfsParent gptkb:Briviact
gptkb:Phenytoin
gptkbp:bfsLayer 7